Kayla Stover Hielscher, IDWeek 2022: Linezolid as a treatment option for MRSA bacteraemia

Methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia is one of the more severe forms of MRSA. In this touchINFECTIOUS DISEASES interview, we met with Prof. Kayla Stover Hielscher (University of Mississippi School of Pharmacy, Jackson, MS, USA) to discuss the use of linezolid as a treatment option for MRSA bacteraemia infection. Dr Stover Hielscher discusses drug interactions, long term use and potential side effects, and the data that supports its use.

The abstract entitled: ‘This Drug for That Bug: Really? An Evidence-Based Discussion of Antimicrobial Activity Relevant to Antimicrobial Stewardship‘ was presented at IDWeek 2022, 19-23 October 2022.

Interviews available in this series:

Ceftriaxone as a treatment option for MSSA, ensuring optimum activity

Isavuconazole – a good treatment option for Candida species?

Questions:

1. What are the pros and cons of the use of linezolid for bacteremia?
2. What data supports the use of linezolid?
3. In which situations should its use be avoided?

Disclosures: Kayla Stover Hielscher has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of IDWeek 2022